<DOC>
	<DOCNO>NCT01011192</DOCNO>
	<brief_summary>The aim study assess clinical performance two different ke0s ( fast slow ) term propofol effect-site concentration ( Ce ) loss recovery consciousness , use Marsh 's pharmacokinetic model.The hypothesis test Ce propofol predict slow ke0 loss recovery consciousness similar , differently fast ke0 .</brief_summary>
	<brief_title>Performance Two Different ke0s Same Pharmacokinetic Propofol Model</brief_title>
	<detailed_description>Introduction : The ke0 define proportional variation gradient concentration plasma effect-site relation unit time . Theoretically , high value ke0 , fast drug enters effect-site . Therefore , drug short T½ke0 high ke0s fast onset action . The aim study assess clinical performance two different ke0s ( fast slow ) term propofol effect-site concentration ( Ce ) loss recovery consciousness , use Marsh 's pharmacokinetic model . Method : Twenty healthy male adult volunteer participate study . Propofol first administer individual volunteer use Marsh 's pharmacokinetic target-controlled infusion model ke0 1.21 min-1 , another opportunity , pharmacokinetic model ke0 0.26 min-1 . Propofol infuse plasma target-concentration 3.0 µg.mL-1 . Loss recovery consciousness define response volunteer verbal stimulus . The Ce register moment loss recovery consciousness . Results : At loss recovery consciousness , propofol Ce mean predict fast ke0 different ( 3.64 ± 0.78 1.47 ± 0.29 µg.mL-1 , respectively , p &lt; 0.0001 ) , whereas slow ke0 predict Ce mean similar ( 2.20 ± 0.70 2.13 ± 0.43 µg.mL-1 , respectively , p = 0.5425 ) . Conclusion : It conclude slow ke0 ( 0.26 min-1 ) incorporate Marsh 's pharmacokinetic model show well clinical performance fast ke0 ( 1.21 min-1 ) , since predict effect-site concentration propofol loss recovery consciousness similar .</detailed_description>
	<mesh_term>Unconsciousness</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<criteria>healthy male adult 20 45 year old use alcohol illicit drug chronic use H2 inhibitor tricyclic antidepressant calcium channel blocker hypersensitivity drug use experimental protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Intravenous anesthesia</keyword>
	<keyword>propofol</keyword>
	<keyword>pharmacokinetic model</keyword>
	<keyword>Monitoring</keyword>
	<keyword>bispectral index .</keyword>
</DOC>